Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: To present a nomogram for prediction of overall survival (OS) in patients with locally advanced cervical cancer (LACC) undergoing definitive radiochemotherapy including image-guided adaptive brachytherapy (IGABT).

Methods And Materials: Seven hundred twenty patients with LACC treated with radiochemotherapy including IGABT in 12 institutions (median follow-up 56 months) were analyzed; 248 deaths occurred. Thirteen candidate predictors for OS were a priori chosen on the basis of the literature and expert knowledge. Missing data (7.2%) were imputed using multiple imputation and predictive mean matching. Univariate analysis with a multivariable Cox regression model for OS stratified by center was performed. Stepwise selection of predictive factors with the Akaike Information Criterion was used to obtain a predictive model and construct a nomogram for OS predictions 60 months from diagnosis; this was internally validated by concordance probability as a measure of discrimination and a calibration plot.

Results: Thirteen potential predictive factors were evaluated; 10 factors reached statistical significance in univariate analysis (age, Hemoglobin, FIGO Stage, tumor width, corpus involvement, lymph node involvement, concurrent chemotherapy, dose to 90% of the high-risk clinical target volume volume of CTV at the first brachytherapy [CTVVolumeBT], overall treatment time [OTT]). Four factors were confirmed significant within the multivariable Cox regression model (FIGO Stage, lymph node involvement, concurrent chemotherapy, CTVVolumeBT). The predictive model and corresponding nomogram were based on 7 Akaike Information Criterion-selected factors (age, corpus involvement, FIGO Stage, lymph node involvement, concurrent chemotherapy, CTVVolumeBT, OTT) and showed promising calibration and discrimination (cross-validated concordance probability c = 0.73).

Conclusions: This is the first nomogram to predict OS in patients with LACC treated with IGABT. In addition to previously reported factors (age, FIGO stage, corpus involvement, chemotherapy delivery, OTT, lymph node involvement), status of primary tumor at the time of brachytherapy seems to be an essential outcome predictor. These results can facilitate individualized tailoring of treatment and patient counseling during the treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2021.04.022DOI Listing

Publication Analysis

Top Keywords

figo stage
16
lymph node
16
node involvement
16
radiochemotherapy including
12
corpus involvement
12
involvement concurrent
12
concurrent chemotherapy
12
survival patients
8
patients locally
8
locally advanced
8

Similar Publications

Objective: To investigate the clinical utility of diagnostic laparoscopy in guiding treatment strategy and surgical outcomes for patients with advanced-stage ovarian cancer, specifically regarding operability assessment and the likelihood of complete cytoreduction.

Methods: This retrospective cohort study analyzed 183 patients with histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) stage III-IV ovarian cancer treated with curative intent between January 2018 and December 2023 at a tertiary referral center. Patients were divided into two groups: those who underwent diagnostic laparoscopy prior to primary treatment (n = 80) and those managed without laparoscopy (n = 103).

View Article and Find Full Text PDF

BACKGROUND This study reports on 2 cases of cervical melanoma with similar presentations but at different stages, and the treatment strategy varied accordingly, and we review the literature on the characteristics, diagnosis, and management of cervical melanoma. CASE REPORT Case 1: A 69-year-old woman with abnormal vaginal bleeding was diagnosed with advanced cervical melanoma, staged as International Federation of Gynecology and Obstetrics (FIGO) Stage IVB, involving multiple metastases. Despite chemoradiotherapy and immunotherapy (nivolumab), the disease progressed rapidly, and the patient died 4 months after diagnosis.

View Article and Find Full Text PDF

Background: High-dose-rate (HDR) brachytherapy is essential in the treatment of locally advanced cervical cancer. While Iridium-192 (Ir-192) is commonly used, its short half-life imposes logistical and financial constraints, particularly in low- and middle-income countries (LMICs). Cobalt-60 (Co-60), with a longer half-life and lower operational costs, is a viable alternative.

View Article and Find Full Text PDF

Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer.

Open Med (Wars)

August 2025

Department of Gynecological Oncology, Tianjin Central Hospital of Gynecology and Obstetrics, No. 156, Nankai Sanma Road, Xingnan Street, Nankai District, Tianjin, 300100, China.

Background: The exosomal microRNAs (exomiRNAs) are promising novel biomarkers for clinical detection and prognosis assessment of human cancers. The aim of this study was to identify potential exomiRNAs as biomarkers in ovarian cancer (OC).

Methods: The candidate exomiRNAs were screened by analysis of GSE235525, GSE239685, and GSE216150 datasets and further validated in exosome samples from the serum of 61 patients with OC and OC cell lines by qPCR.

View Article and Find Full Text PDF

PD-L1 expression in locally advanced cervical cancer: A pilot cross clone comparison study.

Int J Radiat Oncol Biol Phys

September 2025

Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Electronic address:

Purpose: Recent immunotherapy trials in locally advanced cervical cancer report high PD-L1 positivity rates whereas academic multicentric initiatives report a lower PD-L1 positivity. These observations necessitate cross-clone comparison to understand the observed differences.

Methods: Two different clones used in previous multicentric international studies SP142 (BIOEMBRACE) and 22C3 (KEYNOTE-A18) were used to test PD-L1 positivity in a pilot cohort of FIGO 2018 stage III cervical cancer patients recruited in a phase III trial.

View Article and Find Full Text PDF